AVID RADIOPHARMACEUTICALS PHASE II RESULTS FEATURED IN TWO PRESENTATIONS AT ALZHEIMER'S ASSOCIATION 2009 INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE (ICAD)

Trial Results Show Increased Amyloid Burden Detected with ^{18}F- AV-45 PET in Alzheimer's Disease (AD) and Mild Cognitive (MCI) versus Healthy Control (HC) Population

Philadelphia, PA, July 13, 2009 – Avid Radiopharmaceuticals, Inc., a leader in the development of molecular imaging products, announced today that two presentations were made on the Company's ^{18}F-AV-45 PET radiopharmaceutical for the molecular imaging of amyloid aggregates in the brain at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease meeting, being held in Vienna, Austria, from July 11-16, 2009.

One of the main conclusions of Avid's Phase II study is that elevated brain amyloid levels in cognitively normal subjects, as measured by ^{18}F-AV-45 PET imaging, are associated with decreased memory performance. A second, important conclusion is that the mean ^{18}F-AV-45 retention values in the brain differed significantly between healthy control (HC) and Alzheimer's disease (AD) populations ($p<0.001$). In addition, Avid's Phase II study found that MCI brain amyloid levels, on average, fall in between HC and AD subjects, with individual patient results reflecting one extreme (e.g. high, AD-like, amyloid levels) or the other (e.g. low, HC-like, amyloid levels).

PRESENTATIONS

- Dr. Reisa Sperling, Massachusetts General Hospital, Boston, MA, USA, presented a poster on behalf of the Avid Phase II ^{18}F-AV-45-A05 trial group, entitled: "PET imaging of β-amyloid with florpiramine F18 (^{18}F-AV-45): Preliminary results from a Phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and subjects with a clinical diagnosis of Alzheimer's disease."
- Dr. P. Murali Doraiswamy, Duke University Medical Center, Durham, NC, USA, made an oral presentation on behalf of the Avid Phase II ^{18}F-AV-45-A05 trial group entitled: "Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with AD: Phase II results from a florpiramine F18 PET imaging study."

"The results of this multi-center Phase II AV-45 trial are very informative and extend the accumulating data obtained with 11C-PIB PET imaging," comments Dr. Dorasiwamy. "This is the first in vivo 18F-amyloid imaging data to reinforce previous evidence that amyloid deposition is an early precursor to the development of Alzheimer's disease. In addition, these results point to the need for further study of the earlier treatment of

elevated amyloid levels in the brain with the goal of slowing the progression of this devastating disease."

Avid is a leading company in the development of novel molecular imaging compounds intended for the early detection and monitoring of significant chronic human diseases. Avid's ^{18}F-AV-45 was the first amyloid imaging compound to enter multi-center, IND-approved, clinical studies in the U.S., and has now been studied in more than 350 individuals, ranging from cognitively normal individuals to those with Alzheimer's disease. ^{18}F-AV-45 entered a pivotal registration study using a unique trial design that was based upon recommendations by the FDA neurology advisory committee in October 2008.

About Avid Radiopharmaceuticals Inc.
Based in Philadelphia, PA, Avid Radiopharmaceuticals Inc. is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. The company is a pioneer in the development of molecular imaging agents for Alzheimer's disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently conducting Phase III clinical studies of ^{18}F-AV-45 for imaging amyloid plaques in Alzheimer's disease, and is in Phase I and II trials with ^{18}F-AV-133 for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration (Parkinson's disease and Dementia with Lewy Bodies) and beta cell dysfunction (Type I and Type II Diabetes Mellitus). More information about Avid is available at www.avidrp.com.

CONTACT:
Alan P. Carpenter Jr., Ph.D.
VP, Business Development, Legal and Regulatory Affairs
215-966-6173
carpenter@avidrp.com

###